http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011514517-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-102 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543 |
| filingDate | 2009-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2011514517-A |
| titleOfInvention | Method for assaying antibodies against cyclic citrullinated peptides |
| abstract | The present invention relates to a method for assaying anti-cyclic citrullinated peptide antibodies in a clinical sample, wherein the sample is contacted with at least one homogeneous reagent comprising at least one specific binder for anti-CCP antibodies, and homogeneous. Forming a solution or suspension of an anti-CCP binding partner complex in a sample mixture and detecting the presence or level of said anti-CCP binding partner complex in a homogeneous liquid phase. The present invention is also a method for assessing the presence, risk, likelihood or trend of RA in a subject, wherein the anti-CCP in said subject's body sample is assayed in a homogeneous assay according to the present invention, wherein said Measuring the level of the anti-CCP antibody and associating the level thus measured with the presence, risk, likelihood or trend of RA in said subject. [Selection figure] None |
| priorityDate | 2008-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.